James Herndon,

Department:
Biostatistics and Bioinformatics

Email Address:
hernd001@mc.duke.edu

Address:
DUMC Box 2717
DUMC
Durham, NC 27710

Research Interests:
Current research interests have application to the design and analysis of cancer clinical trials.  Specifically, interests include the use of time-dependent covariables within survival models, the design of phase II cancer clinical trials which minimize some of the logistical problems associated with their conduct, and the analysis of longitudinal studies with informative censoring (in particular, quality of life studies of patients with advanced cancer).

Publications:
2009 -- Pubmed # 19096882 -- Abernethy AP, Barbour SY, Uronis H, Zafar SY, Coan A, Rowe K, Pupa MR, Wheeler JL, Herndon JE 2nd. Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. Support Care Cancer. 2009 Jun;17(6):735-44.

2009 -- Pubmed # 19394793 -- Abernethy AP, Herndon JE 2nd, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lyerly HK. Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manage. 2009 Jun;37(6):1027-38.

2009 -- Pubmed # 19514083 -- Affronti ML, Heery CR, Herndon JE 2nd, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009 Aug 1;115(15):3501-11.

2009 -- Pubmed # 18536022 -- Alfano CM, Day JM, Katz ML, Herndon JE 2nd, Bittoni MA, Oliveri JM, Donohue K, Paskett ED. Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804. Psychooncology. 2009 Feb;18(2):128-33.

2009 -- Pubmed # 19117348 -- Birchard KR, Hoang JK, Herndon JE Jr, Patz EF Jr. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2009 Feb 1;115(3):581-6.

2009 -- Pubmed # 19507456 -- Dupont A, Wheeler J, Herndon JE 2nd, Coan A, Zafar SY, Hood L, Patwardhan M, Shaw HS, Lyerly HK, Abernethy AP. Use of tablet personal computers for sensitive patient-reported information. J Support Oncol. 2009 May-Jun;7(3):91-7.

2009 -- Pubmed # 19133656 -- Katz ML, Donohue KA, Alfano CM, Day JM, Herndon JE 2nd, Paskett ED. Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804. Cancer. 2009 Feb 1;115(3):480-8.

2009 -- Pubmed # 19170232 -- Paskett E, Herndon J 2nd, Donohue K, Naughton M, Grubbs S, Pavy M, Hensley M, Stark N, Kornblith A, Bittoni M, . Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. Cancer. 2009 Mar 1;115(5):1109-20.

2009 -- Pubmed # 19188181 -- Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009 Feb 1;15(3):1064-8.

2009 -- Pubmed # 19533023 -- Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol. 2009 Jun 17.

2009 -- Pubmed # 19402172 -- Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Friedman HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 2009 Jul 1;115(13):2964-70.

2009 -- Pubmed # 19204199 -- Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE 2nd, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7.

2009 -- Pubmed # 19562254 -- Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE 2nd, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2009 Jun 28.

2009 -- Pubmed # 19248046 -- Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009 May 15;115(10):2188-98.

2009 -- Pubmed # 19228619 -- Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19;360(8):765-73.

2008 -- Pubmed # 18761678 -- Abernethy AP, Herndon JE 2nd, Wheeler JL, Patwardhan M, Shaw H, Lyerly HK, Weinfurt K. Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data. Health Serv Res. 2008 Dec;43(6):1975-91.

2008 -- Pubmed # 18314416 -- Arnold SD, Forman LM, Brigidi BD, Carter KE, Schweitzer HA, Quinn HE, Guill AB, Herndon JE 2nd, Raynor RH. Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neuro Oncol. 2008 Apr;10(2):171-81.

2008 -- Pubmed # 18367288 -- Bogart JA, Watson D, McClay EF, Evans L, Herndon JE, Laurie F, Seagren SL, Fitzgerald TJ, Vokes E, Green MR. Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer. 2008 Oct;62(1):92-8.

2008 -- Pubmed # 18805257 -- Burfeind WR Jr, Tong BC, O'Branski E, Herndon JE, Toloza EM, D'Amico TA, Harpole LH, Harpole DH Jr. Quality of life outcomes are equivalent after lobectomy in the elderly. J Thorac Cardiovasc Surg. 2008 Sep;136(3):597-604.

2008 -- Pubmed # 18981004 -- Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 1;14(21):7068-73.

2008 -- Pubmed # 18303437 -- Graziano SL, Herndon JE 2nd, Socinski MA, Wang X, Watson D, Vokes E, Green MR, . Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 2008 Feb;3(2):158-62.

2008 -- Pubmed # 18536973 -- Greenberg JA, Shibata D, Herndon JE 2nd, Steele GD Jr, Mayer R, Bleday R. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008 Aug;51(8):1185-91; discussion 1191-4.

2008 -- Pubmed # 18757325 -- Herndon JE 2nd, Kornblith AB, Holland JC, Paskett ED. Patient education level as a predictor of survival in lung cancer clinical trials. J Clin Oncol. 2008 Sep 1;26(25):4116-23.

2008 -- Pubmed # 18349396 -- Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE 2nd, Patz EF Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008 Mar 20;26(9):1459-64.

2008 -- Pubmed # 18388845 -- Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA, . Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar;46(3):303-8.

2008 -- Pubmed # 17634939 -- Ochiai H, Archer GE, Herndon JE 2nd, Kuan CT, Mitchell DA, Bigner DD, Pastan IH, Sampson JH. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother. 2008 Jan;57(1):115-21.

2008 -- Pubmed # 18792786 -- Oliveri JM, Day JM, Alfano CM, Herndon JE 2nd, Katz ML, Bittoni MA, Donohue K, Paskett ED. Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804. J Cancer Surviv. 2008 Dec;2(4):233-42.

2008 -- Pubmed # 18314912 -- Paskett ED, Herndon JE 2nd, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA, . Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Nov;17(11):1108-20.

2008 -- Pubmed # 18359865 -- Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008 Jun;10(3):330-40.

2008 -- Pubmed # 18287339 -- Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr;10(2):182-9.

2008 -- Pubmed # 18403491 -- Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE 2nd, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008 Jun;10(3):320-9.

2008 -- Pubmed # 18182667 -- Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008 Jan 10;26(2):271-8.

2008 -- Pubmed # 18775433 -- Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE 2nd, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339(1):74-81.

2008 -- Pubmed # 18978566 -- Stinchcombe TE, Mauer AM, Hodgson LD, Herndon JE 2nd, Lynch TJ, Green MR, Vokes EE, . Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. J Thorac Oncol. 2008 Nov;3(11):1301-7.

2008 -- Pubmed # 18809614 -- Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 1;26(31):5043-51.

2008 -- Pubmed # 19032772 -- Zafar SY, Abernethy AP, Abbott DH, Grambow SC, Marcello JE, Herndon JE 2nd, Rowe KL, Kolimaga JT, Zullig LL, Patwardhan MB, Provenzale DT. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer. 2008;8:345.

2007 -- Pubmed # 17108065 -- Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 2007 Jan;9(1):70-4.

2007 -- Pubmed # 17245623 -- Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May;83(1):53-60.

2007 -- Pubmed # 17545844 -- Gauger J, Patz EF Jr, Coleman RE, Herndon JE 2nd. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. J Thorac Oncol. 2007 Jun;2(6):499-505.

2007 -- Pubmed # 17347491 -- Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007 Apr;9(2):161-8.

2007 -- Pubmed # 17918261 -- Hoagland LF 4th, Campa MJ, Gottlin EB, Herndon JE 2nd, Patz EF Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer. 2007 Nov 15;110(10):2260-8.

2007 -- Pubmed # 17638879 -- Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 2007 Jul 15;67(14):6691-9.

2007 -- Pubmed # 17607117 -- Loewen GM, Watson D, Kohman L, Herndon JE 2nd, Shennib H, Kernstine K, Olak J, Mador MJ, Harpole D, Sugarbaker D, Green M, . Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238. J Thorac Oncol. 2007 Jul;2(7):619-25.

2007 -- Pubmed # 17499730 -- McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE 2nd, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 2007 May;34(4):405-13.

2007 -- Pubmed # 18065730 -- Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007 Dec 10;25(35):5578-83.

2007 -- Pubmed # 17545847 -- Riedel RF, Andrews C, Garst J, Dunphy F, Herndon JE 2nd, Blackwell S, Barbour S, Crawford J. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. J Thorac Oncol. 2007 Jun;2(6):520-5.

2007 -- Pubmed # 17065590 -- Rocha-Lima CM, Herndon JE 2nd, Lee ME, Atkins JN, Mauer A, Vokes E, Green MR, . Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol. 2007 Feb;18(2):331-7.

2007 -- Pubmed # 17435179 -- Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE 2nd, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodríguez-Ponce MI, Tanner P, Puri R, Pedain C. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol. 2007 Jul;9(3):343-53.

2007 -- Pubmed # 17971599 -- Swanson SJ, Herndon JE 2nd, D'Amico TA, Demmy TL, McKenna RJ Jr, Green MR, Sugarbaker DJ. Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol. 2007 Nov 1;25(31):4993-7.

2007 -- Pubmed # 17404369 -- Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR, . Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704.

2007 -- Pubmed # 17317837 -- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15;13(4):1253-9.

2007 -- Pubmed # 17947719 -- Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20;25(30):4722-9.

2006 -- Pubmed # 16488712 -- Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE 2nd, Landreneau RJ, Inculet RI, Jones DR, Meyers BF, Harpole DH, Putnam JB Jr, Rusch VW, . Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006 Mar;81(3):1013-9; discussion 1019-20.

2006 -- Pubmed # 16904841 -- Anscher MS, Garst J, Marks LB, Larrier N, Dunphy F, Herndon JE 2nd, Clough R, Marino C, Vujaskovic Z, Zhou S, Dewhirst MW, Shafman TD, Crawford J. Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):477-82.

2006 -- Pubmed # 16365181 -- Blackstock AW, Herndon JE 2nd, Paskett ED, Miller AA, Lathan C, Niell HB, Socinski MA, Vokes EE, Green MR, . Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Clin Oncol. 2006 Jan 20;24(3):407-12.

2006 -- Pubmed # 16943537 -- Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM 3rd, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL Jr, Chadaram V, Herndon JE 2nd, Fraker DL, Tyler DS, . Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006 Sep 1;24(25):4196-201.

2006 -- Pubmed # 16731117 -- D'Amico TA, Brooks KR, Joshi MB, Conlon D, Herndon J 2nd, Petersen RP, Harpole DH Jr. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. Ann Thorac Surg. 2006 Jun;81(6):1982-7; discussion 1987.

2006 -- Pubmed # 16540683 -- Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006 Mar 15;66(6):3294-302.

2006 -- Pubmed # 17163259 -- Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Clin Drug Investig. 2006;26(5):257-66.

2006 -- Pubmed # 17039491 -- Jaklitsch MT, Herndon JE 2nd, DeCamp MM Jr, Richards WG, Kumar P, Krasna MJ, Green MR, Sugarbaker DJ. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol. 2006 Dec 1;94(7):599-606.

2006 -- Pubmed # 16505413 -- Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403.

2006 -- Pubmed # 17078057 -- Kornblith AB, Dowell JM, Herndon JE 2nd, Engelman BJ, Bauer-Wu S, Small EJ, Morrison VA, Atkins J, Cohen HJ, Holland JC. Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. Cancer. 2006 Dec 1;107(11):2706-14.

2006 -- Pubmed # 16609006 -- Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82.

2006 -- Pubmed # 16985253 -- Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA, . Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20;98(18):1335-8.

2006 -- Pubmed # 17041097 -- Maxwell JA, Johnson SP, Quinn JA, McLendon RE, Ali-Osman F, Friedman AH, Herndon JE 2nd, Bierau K, Bigley J, Bigner DD, Friedman HS. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther. 2006 Oct;5(10):2531-9.

2006 -- Pubmed # 16382120 -- Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 1;24(1):115-22.

2006 -- Pubmed # 16741299 -- Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006 Jun;47(6):912-8.

2006 -- Pubmed # 16467100 -- Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8.

2006 -- Pubmed # 17005294 -- Riedel RF, Crawford J, Dunphy F, Herndon JE 2nd, Garst J, Kelley MJ. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer. 2006 Dec;54(3):431-2.

2006 -- Pubmed # 17003785 -- Vlahovic G, Rabbani ZN, Herndon JE 2nd, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer. 2006 Oct 23;95(8):1013-9.

2006 -- Pubmed # 16514477 -- Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006 Apr;13(4):491-500.

2005 -- Pubmed # 16098244 -- Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer. 2005 Jul;7(1):47-53.

2005 -- Pubmed # 15751020 -- Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M, . Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005 Apr 15;103(8):1670-5.

2005 -- Pubmed # 15829324 -- D'Cunha J, Herndon JE 2nd, Herzan DL, Patterson GA, Kohman LJ, Harpole DH, Kernstine KH, Kern JA, Green MR, Maddaus MA, Kratzke RA, . Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer. 2005 May;48(2):241-6.

2005 -- Pubmed # 15764775 -- Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ, , , , . Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005 Mar;127(3):909-15.

2005 -- Pubmed # 15788680 -- Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, Green MR, Kindler HL, . Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15;11(6):2300-4.

2005 -- Pubmed # 15868443 -- Hensley ML, Dowell J, Herndon JE 2nd, Winer E, Stark N, Weeks JC, Paskett E. Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat. 2005 May;91(2):153-61.

2005 -- Pubmed # 15788669 -- Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005 Mar 15;11(6):2215-21.

2005 -- Pubmed # 15824161 -- Kelley MJ, Glaser EM, Herndon JE 2nd, Becker F, Bhagat R, Zhang YJ, Santella RM, Carmella SG, Hecht SS, Gallot L, Schilder L, Crowell JA, Perloff M, Folz RJ, Bergan RC. Safety and efficacy of weekly oral oltipraz in chronic smokers. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):892-9.

2005 -- Pubmed # 15731371 -- Kim YH, Marom EM, Herndon JE 2nd, McAdams HP. Pulmonary vein diameter, cross-sectional area, and shape: CT analysis. Radiology. 2005 Apr;235(1):43-9; discussion 49-50.

2005 -- Pubmed # 15893012 -- Kindler HL, Herndon JE, Zhang C, Green MR, . Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005 Jun;48(3):423-8.

2005 -- Pubmed # 16030306 -- Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20;97(14):1080-3.

2005 -- Pubmed # 16164916 -- Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, Hunt KK, Giuliano AE. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. Am J Surg. 2005 Oct;190(4):539-42.

2005 -- Pubmed # 15625373 -- Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005 Jan 1;23(1):190-6.

2005 -- Pubmed # 15685040 -- McClay EF, Bogart J, Herndon JE 2nd, Watson D, Evans L, Seagren SL, Green MR, . A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol. 2005 Feb;28(1):81-90.

2005 -- Pubmed # 16116609 -- McLendon RE, Herndon JE 2nd, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 2005 Oct 15;104(8):1693-9.

2005 -- Pubmed # 15893009 -- Miller AA, Herndon JE 2nd, Gu L, Green MR, . Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer. 2005 Jun;48(3):399-407.

2005 -- Pubmed # 15923572 -- Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR, . Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005 Jun 1;23(16):3752-9.

2005 -- Pubmed # 16118805 -- Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15;104(8):1580-9.

2005 -- Pubmed # 16192820 -- Posther KE, McCall LM, Blumencranz PW, Burak WE Jr, Beitsch PD, Hansen NM, Morrow M, Wilke LG, Herndon JE 2nd, Hunt KK, Giuliano AE. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005 Oct;242(4):593-9; discussion 599-602.

2005 -- Pubmed # 16192602 -- Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 1;23(28):7178-87.

2005 -- Pubmed # 16361636 -- Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN Sr, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20;23(36):9359-68.

2005 -- Pubmed # 16088964 -- Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005 Oct 1;104(7):1478-86.

2005 -- Pubmed # 15558802 -- Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005 Jan 15;103(2):329-38.

2005 -- Pubmed # 15821648 -- Shennib H, Bogart J, Herndon JE, Kohman L, Keenan R, Green M, Sugarbaker D, , . Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. J Thorac Cardiovasc Surg. 2005 Apr;129(4):813-8.

2004 -- Pubmed # 15484217 -- Ahles TA, Herndon JE 2nd, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC, . Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15;101(10):2202-8.

2004 -- Pubmed # 15145163 -- Bogart JA, Herndon JE 2nd, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT, Green MR, . 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):460-8.

2004 -- Pubmed # 15140545 -- Cheran SK, Herndon JE 2nd, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004 Jun;44(3):317-25.

2004 -- Pubmed # 15574210 -- Gururangan S, Hwang E, Herndon JE 2nd, Fuchs H, George T, Coleman RE. [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004 Dec;55(6):1280-8; discussion 1288-9.

2004 -- Pubmed # 15541816 -- Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald MC, Bepler G, Patz EF Jr. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer. 2004 Dec;46(3):313-23.

2004 -- Pubmed # 14758128 -- Johnson E, Lake D, Herndon JE 2nd, Box JW, Lynch TJ, Green MR. Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. Am J Clin Oncol. 2004 Feb;27(1):19-23.

2004 -- Pubmed # 15514374 -- Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J, . Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol. 2004 Nov 1;22(21):4329-40.

2004 -- Pubmed # 14739316 -- Marom EM, Herndon JE, Kim YH, McAdams HP. Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation. Radiology. 2004 Mar;230(3):824-9.

2004 -- Pubmed # 15105803 -- McLendon RE, Rasheed A, Wiltshire R, Herndon J. Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma. Mod Pathol. 2004 May;17(5):604-5.

2004 -- Pubmed # 15084390 -- Otterson GA, Herndon JE 2nd, Watson D, Green MR, Kindler HL, . Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004 May;44(2):251-9.

2004 -- Pubmed # 15169809 -- Patz EF Jr, Swensen SJ, Herndon JE 2nd. Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. J Clin Oncol. 2004 Jun 1;22(11):2202-6.

2004 -- Pubmed # 15134629 -- Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE 2nd, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004 Apr;6(2):145-53.

2004 -- Pubmed # 15134628 -- Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004 Apr;6(2):134-44.

2004 -- Pubmed # 14638850 -- Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004 Jan 1;22(1):133-42.

2004 -- Pubmed # 14998842 -- Rocha Lima CM, Rizvi NA, Zhang C, Herndon JE 2nd, Crawford J, Govindan R, King GW, Green MR, . Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol. 2004 Mar;15(3):410-8.

2004 -- Pubmed # 15301880 -- Sherman CA, Herndon JE 2nd, Watson DM, Green MR, . A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004 Sep;45(3):387-92.

2004 -- Pubmed # 15205196 -- Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol. 2004 Jul;15(7):1033-41.

2004 -- Pubmed # 15269292 -- Wiltshire RN, Herndon JE 2nd, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. J Mol Diagn. 2004 Aug;6(3):166-79.

2003 -- Pubmed # 12733147 -- Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15;97(10):2480-6.

2003 -- Pubmed # 12829134 -- Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE, Garst J, Crawford J, Jirtle RL. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):988-95.

2003 -- Pubmed # 14573781 -- Bernacki SH, Stankovic AK, Williams LO, Beck JC, Herndon JE, Snow-Bailey K, Prior TW, Matteson KJ, Wasserman LM, Cole EC, Stenzel TT. Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. J Mol Diagn. 2003 Nov;5(4):227-30.

2003 -- Pubmed # 12842538 -- Brooks KR, To K, Joshi MB, Conlon DH, Herndon JE 2nd, D'Amico TA, Harpole DH Jr. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg. 2003 Jul;76(1):187-93; discussion 193.

2003 -- Pubmed # 12775745 -- Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J 2nd, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 1;21(11):2187-91.

2003 -- Pubmed # 12910510 -- Kornblith AB, Herndon JE 2nd, Weiss RB, Zhang C, Zuckerman EL, Rosenberg S, Mertz M, Payne D, Jane Massie M, Holland JF, Wingate P, Norton L, Holland JC. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003 Aug 15;98(4):679-89.

2003 -- Pubmed # 12832585 -- Marom EM, Palmer SM, Erasmus JJ, Herndon JE, Zhang C, McAdams HP. Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage. Radiology. 2003 Jul;228(1):241-5.

2003 -- Pubmed # 12586801 -- Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE 2nd, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003 Feb 15;21(4):646-51.

2003 -- Pubmed # 14649883 -- Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct;65(1):27-35.

2003 -- Pubmed # 14654545 -- Vollmer RT, Herndon JE 2nd, D'Cunha J, Abraham NZ, Solberg J, Fatourechi M, Maruska A, Kern JA, Green MR, Kratzke RA, Maddaus MA, . Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. Clin Cancer Res. 2003 Nov 15;9(15):5630-5.

2002 -- Pubmed # 11854390 -- Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green MR. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst. 2002 Feb 20;94(4):284-90.

2002 -- Pubmed # 11882819 -- D'Cunha J, Corfits AL, Herndon JE 2nd, Kern JA, Kohman LJ, Patterson GA, Kratzke RA, Maddaus MA. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491.

2002 -- Pubmed # 14653865 -- Elias AD, Kumar P, Herndon J 3rd, Skarin AT, Sugarbaker DJ, Green MR. Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. Clin Lung Cancer. 2002 Sep;4(2):95-103.

2002 -- Pubmed # 12089224 -- Gururangan S, Cavazos CM, Ashley D, Herndon JE 2nd, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 1;20(13):2951-8.

2002 -- Pubmed # 12197224 -- Johnson EA, Klimstra DS, Herndon JE 2nd, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002;20(5-6):686-92.

2002 -- Pubmed # 12011121 -- Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15;20(10):2441-52.

2002 -- Pubmed # 14662044 -- Lyss AP, Herndon JE 2nd, Lynch TJ Jr, Turrisi AT, Watson DM, Grethlein SJ, Green MR. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer. 2002 Feb;3(3):205-10; discussion 211-2.

2002 -- Pubmed # 12076914 -- Marom EM, Erasmus JJ, Herndon JE 2nd, Zhang C, McAdams HP. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions. AJR Am J Roentgenol. 2002 Jul;179(1):105-8.

2002 -- Pubmed # 11997552 -- Marom EM, Sarvis S, Herndon JE 2nd, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002 May;223(2):453-9.

2002 -- Pubmed # 12074261 -- Naughton MJ, Herndon JE 2nd, Shumaker SA, Miller AA, Kornblith AB, Chao D, Holland J. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual Life Res. 2002 May;11(3):235-48.

2002 -- Pubmed # 11980998 -- Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 1;20(9):2277-83.

2002 -- Pubmed # 12173338 -- Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, Friedman AH, Bigner DD, Bigner SH, McLendon RE. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002 May 15;94(10):2688-97.

2002 -- Pubmed # 11870184 -- Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 1;20(5):1389-97.

2002 -- Pubmed # 11815975 -- Rocha Lima CM, Herndon JE 2nd, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002 Jan 1;94(1):181-7.

2002 -- Pubmed # 12377962 -- Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002 Oct 15;20(20):4191-8.

2001 -- Pubmed # 11531010 -- Aloia T, Bepler G, Harpole D, Goodman PC, McAdams HP, Erasmus JJ, Herndon JE, Patz EF Jr. Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities. Cancer Detect Prev. 2001;25(4):336-43.

2001 -- Pubmed # 11565671 -- Aloia TA, Harpole DH Jr, Reed CE, Allegra C, Moore MB, Herndon JE 2nd, D'Amico TA. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg. 2001 Sep;72(3):859-66.

2001 -- Pubmed # 11533099 -- Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE 2nd, Garst J, Crawford J, Jirtle RL. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol. 2001 Sep 1;19(17):3758-65.

2001 -- Pubmed # 11199068 -- Cameron CL, Cella D, Herndon JE 2nd, Kornblith AB, Zuckerman E, Henderson E, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Peterson BA, Holland JC. Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. Health Psychol. 2001 Jan;20(1):71-5.

2001 -- Pubmed # 11603427 -- D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE 2nd, Kinch MS, Harpole DH Jr. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg. 2001 Oct;72(4):1144-8.

2001 -- Pubmed # 11551406 -- Graziano SL, Tatum A, Herndon JE 2nd, Box J, Memoli V, Green MR, Kern JA. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 2001 Aug-Sep;33(2-3):115-23.

2001 -- Pubmed # 11584894 -- Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol. 2001 Oct;3(4):246-50.

2001 -- Pubmed # 11297249 -- Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D'Amico TA, Sporn T, Parr A, Linoila I, Allegra C. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2001 Mar;7(3):562-9.

2001 -- Pubmed # 11753983 -- Heyneman LE, Herndon JE, Goodman PC, Patz EF Jr. Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. Cancer. 2001 Dec 15;92(12):3051-5.

2001 -- Pubmed # 11165412 -- Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001 Feb-Mar;31(2-3):311-7.

2001 -- Pubmed # 11432621 -- Kornblith AB, Herndon JE 2nd, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ, . The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol. 2001 May;12(5):633-41.

2001 -- Pubmed # 11180093 -- Kornblith AB, Herndon JE 2nd, Zuckerman E, Viscoli CM, Horwitz RI, Cooper MR, Harris L, Tkaczuk KH, Perry MC, Budman D, Norton LC, Holland J, . Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer. 2001 Jan 15;91(2):443-54.

2001 -- Pubmed # 11679188 -- Kosty MP, Herndon JE 2nd, Vogelzang NJ, Kindler HL, Green MR. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer. 2001 Nov;34(2):289-95.

2001 -- Pubmed # 11157021 -- Maguire PD, Marks LB, Sibley GS, Herndon JE 2nd, Clough RW, Light KL, Hernando ML, Antoine PA, Anscher MS. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol. 2001 Feb 1;19(3):705-11.

2001 -- Pubmed # 11551404 -- Marom EM, Aloia TA, Moore MB, Hara M, Herndon JE 2nd, Harpole DH Jr, Goodman PC, Patz EF Jr. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001 Aug-Sep;33(2-3):99-107.

2001 -- Pubmed # 14700479 -- Niell HB, Perry MC, Clamon G, Crawford J, Miller AA, Herndon J 2nd, Green MR. Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):204-9.

2001 -- Pubmed # 11396194 -- Salgia R, Harpole D, Herndon JE 2nd, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001 Mar-Apr;21(2B):1241-6.

2001 -- Pubmed # 11182001 -- Socinski MA, Marks LB, Garst J, Sibley GS, Blackstock W, Turrisi A, Herndon J, Zhou S, Anscher M, Crawford J, Shafman T, Rosenman J. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. Oncologist. 2001;6 Suppl 1:20-4.

2000 -- Pubmed # 10705017 -- Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):947-58.

2000 -- Pubmed # 11078500 -- Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000 Nov 15;18(22):3862-72.

2000 -- Pubmed # 10750777 -- D'Amico TA, Aloia TA, Moore MB, Herndon JE 2nd, Brooks KR, Lau CL, Harpole DH Jr. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000 Mar;69(3):882-6.

2000 -- Pubmed # 10831716 -- Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. 2000 Jun;215(3):886-90.

2000 -- Pubmed # 11032594 -- Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE 2nd, Bigner DD, Dolan ME. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2000 Oct 15;18(20):3522-8.

2000 -- Pubmed # 10701623 -- Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol. 2000 Mar;174(3):769-74.

2000 -- Pubmed # 10858384 -- Patz EF Jr, Rossi S, Harpole DH Jr, Herndon JE, Goodman PC. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest. 2000 Jun;117(6):1568-71.

2000 -- Pubmed # 10704711 -- Perry MC, Ihde DC, Herndon JE 2nd, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer. 2000 Apr;28(1):63-8.

1999 -- Pubmed # 10458211 -- Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 1999 Jan;17(1):4-11.

1999 -- Pubmed # 10096969 -- D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999 Apr;117(4):736-43.

1999 -- Pubmed # 10541115 -- Hara M, McAdams HP, Vredenburgh JJ, Herndon JE, Patz EF Jr. Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer. AJR Am J Roentgenol. 1999 Nov;173(5):1341-4.

1999 -- Pubmed # 10023700 -- Herndon JE 2nd, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999 Jan 15;85(2):333-40.

1999 -- Pubmed # 10570422 -- Kindler HL, Belani CP, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999 Nov 15;86(10):1985-91.

1999 -- Pubmed # 10477012 -- Maguire PD, Sibley GS, Zhou SM, Jamieson TA, Light KL, Antoine PA, Herndon JE 2nd, Anscher MS, Marks LB. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):97-103.

1999 -- Pubmed # 10478250 -- Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, Herndon JE, Patz EF Jr. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999 Sep;212(3):803-9.

1999 -- Pubmed # 9885620 -- Marom EM, Patz EF Jr, Erasmus JJ, McAdams HP, Goodman PC, Herndon JE. Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology. 1999 Jan;210(1):277-81.

1999 -- Pubmed # 10405720 -- Patz EF Jr, Erasmus JJ, McAdams HP, Connolly JE, Marom EM, Goodman PC, Leder RA, Keogan MT, Herndon JE. Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology. 1999 Jul;212(1):56-60.

1999 -- Pubmed # 9921973 -- Shieh DB, Godleski J, Herndon JE 2nd, Azuma T, Mercer H, Sugarbaker DJ, Kwiatkowski DJ. Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer. 1999 Jan 1;85(1):47-57.

1999 -- Pubmed # 10458680 -- Steele GD Jr, Herndon JE, Bleday R, Russell A, Benson A 3rd, Hussain M, Burgess A, Tepper JE, Mayer RJ. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41.

1999 -- Pubmed # 10416012 -- Vogelzang NJ, Herndon JE 2nd, Miller A, Strauss G, Clamon G, Stewart FM, Aisner J, Lyss A, Cooper MR, Suzuki Y, Green MR. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol. 1999 May;10(5):597-600.

1998 -- Pubmed # 9586915 -- Ahles TA, Silberfarb PM, Herndon J 2nd, Maurer LH, Kornblith AB, Aisner J, Perry MC, Eaton WL, Zacharski LL, Green MR, Holland JC. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol. 1998 May;16(5):1954-60.

1998 -- Pubmed # 9731895 -- Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998 Sep 1;83(5):918-24.

1998 -- Pubmed # 9596310 -- Assi Z, Caruso JL, Herndon J, Patz EF Jr. Cytologically proved malignant pleural effusions: distribution of transudates and exudates. Chest. 1998 May;113(5):1302-4.

1998 -- Pubmed # 9626222 -- Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998 Jun;16(6):2202-12.

1998 -- Pubmed # 9817271 -- Choi NC, Herndon JE 2nd, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998 Nov;16(11):3528-36.

1998 -- Pubmed # 9493137 -- Clamon G, Herndon J, Akerley W, Green M. Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung Cancer. 1998 Jan;19(1):25-9.

1998 -- Pubmed # 9817277 -- Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold SC Jr. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 1998 Nov;16(11):3570-5.

1998 -- Pubmed # 9613779 -- Graham ML, Asselin BL, Herndon JE 2nd, Casey JR, Chaffee S, Ciocci GH, Daeschner CW, Davis AR, Gold S, Halperin EC, Laughlin MJ, Martin PL, Olson JF, Kurtzberg J. Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant. 1998 May;21(9):879-85.

1998 -- Pubmed # 9857998 -- Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H, Green MR. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 1998 Sep;21(3):203-11.

1998 -- Pubmed # 9741865 -- Herndon JE 2nd. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin Trials. 1998 Oct;19(5):440-50.

1998 -- Pubmed # 9515850 -- Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998 Mar;113(3):723-31.

1998 -- Pubmed # 9602264 -- Kornblith AB, Herndon JE 2nd, Zuckerman E, Cella DF, Cherin E, Wolchok S, Weiss RB, Diehl LF, Henderson E, Cooper MR, Schiffer C, Canellos GP, Mayer RJ, Silver RT, Schilling A, Peterson BA, Greenberg D, Holland JC. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998 Mar;9(3):297-306.

1998 -- Pubmed # 9667266 -- Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE 2nd, Shieh DB, Richards W, Blanco R, Xu HJ, Strauss GM, Sugarbaker DJ. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol. 1998 Jul;16(7):2468-77.

1998 -- Pubmed # 9726444 -- Mehdi SA, Perry MC, Herndon JE 2nd, Crawford J, Young R, Graziano SL. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. J Interferon Cytokine Res. 1998 Aug;18(8):623-7.

1998 -- Pubmed # 9596311 -- Patz EF Jr, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Gilkeson RC, Herndon J. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 1998 May;113(5):1305-11.

1998 -- Pubmed # 9667265 -- Perry MC, Herndon JE 3rd, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol. 1998 Jul;16(7):2466-7.

1998 -- Pubmed # 9438693 -- Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998 Jan;113(1 Suppl):66S-73S.

1998 -- Pubmed # 9554537 -- Samuels BL, Herndon JE 2nd, Harmon DC, Carey R, Aisner J, Corson JM, Suzuki Y, Green MR, Vogelzang NJ. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer. 1998 Apr 15;82(8):1578-84.

1997 -- Pubmed # 9129444 -- Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE, Goodman PC. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997 May;168(5):1357-60.

1997 -- Pubmed # 9164190 -- Graham ML, Herndon JE 2nd, Casey JR, Chaffee S, Ciocci GH, Krischer JP, Kurtzberg J, Laughlin MJ, Longee DC, Olson JF, Paleologus N, Pennington CN, Friedman HS. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol. 1997 May;15(5):1814-23.

1997 -- Pubmed # 9366296 -- Greenberg DB, Kornblith AB, Herndon JE, Zuckerman E, Schiffer CA, Weiss RB, Mayer RJ, Wolchok SM, Holland JC. Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. Cancer. 1997 Nov 15;80(10):1936-44.

1997 -- Pubmed # 9257067 -- Herndon JE 2nd, Fleishman S, Kosty MP, Green MR. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Control Clin Trials. 1997 Aug;18(4):286-300.

1997 -- Pubmed # 9020283 -- Luikart SD, Herndon JE 2nd, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). Am J Clin Oncol. 1997 Feb;20(1):24-30.

1997 -- Pubmed # 9363869 -- Maurer LH, Herndon JE 2nd, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 Nov;15(11):3378-87.

1997 -- Pubmed # 9179072 -- Vogelzang NJ, Herndon JE 2nd, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.  Cancer.  1997 Jun 1;79(11):2237-42.

1997 -- Pubmed # 9207317 -- Vokes EE, Leopold KA, Herndon J, Green MR. Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-42-S8-45.

1996 -- Pubmed # 9816257 -- Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE 2nd, Vick NA, Paleologos N, Fredericks RK, Schold SC Jr, Bigner DD. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res. 1996 Jun;2(6):963-72.

1996 -- Pubmed # 8780630 -- Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5.

1996 -- Pubmed # 8794413 -- Graziano SL, Valone FH, Herndon JE 2nd, Crawford J, Richards F 2nd, Rege VB, Clamon G, Green MR. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 1996 Jun;14(2-3):315-29.

1996 -- Pubmed # 8598355 -- Halperin EC, Herndon J, Schold SC, Brown M, Vick N, Cairncross JG, Macdonald DR, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel GC, Friedman A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):793-802.

1996 -- Pubmed # 8633961 -- Harpole DH Jr, Richards WG, Herndon JE 2nd, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg. 1996 May;61(5):1470-6.

1996 -- Pubmed # 8635112 -- Kumar P, Herndon J 2nd, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer. 1996 Jun 1;77(11):2393-9.

1996 -- Pubmed # 8882988 -- Mitchell EP, Perry MC, Luikart SD, Cirrincione CT, Van Echo DA, Herndon JE 2nd, Maurer LH, Clamon G, Green MR. A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. Lung Cancer. 1996 Sep;15(2):215-23.

1996 -- Pubmed # 8627642 -- Tross S, Herndon J 2nd, Korzun A, Kornblith AB, Cella DF, Holland JF, Raich P, Johnson A, Kiang DT, Perloff M, Norton L, Wood W, Holland JC. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst. 1996 May 15;88(10):661-7.

1995 -- Pubmed # 9815955 -- Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, Herndon JE 2nd, Pastan IH. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin Cancer Res. 1995 Dec;1(12):1545-55.

1995 -- Pubmed # 7847262 -- Bitran JD, Green M, Perry M, Hollis DR, Herndon JE 2nd. A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. Am J Clin Oncol. 1995 Feb;18(1):67-70.

1995 -- Pubmed # 7805040 -- Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995 Jan 1;55(1):51-6.

1995 -- Pubmed # 8625181 -- Harpole DH Jr, Herndon JE 2nd, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995 Sep 1;76(5):787-96.

1995 -- Pubmed # 9816029 -- Harpole DH Jr, Marks JR, Richards WG, Herndon JE 2nd, Sugarbaker DJ. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res. 1995 Jun;1(6):659-64.

1995 -- Pubmed # 8552891 -- Herndon JE 2nd, Harrell FE Jr. The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. Stat Med. 1995 Oct 15;14(19):2119-29.

1995 -- Pubmed # 7751903 -- Kosty MP, Herndon JE 2nd, Green MR, McIntyre OR. Placebo-controlled randomized study of hydrazine sulfate in lung cancer. J Clin Oncol. 1995 Jun;13(6):1529-30.

1995 -- Pubmed # 7636529 -- Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, Green MR. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1995 Aug;13(8):1871-9.

1995 -- Pubmed # 8719068 -- Muscato JJ, Cirrincione C, Clamon G, Perry MC, Omura G, Berkowitz I, Reid T, Herndon JE 2nd, Green MR. Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. Lung Cancer. 1995 Dec;13(3):285-94.

1995 -- Pubmed # 7708720 -- Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, Pai LH, Herndon J, Bigner DD. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2765-9.

1995 -- Pubmed # 7497771 -- Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 1995 Dec;108(6):1617-21.

1995 -- Pubmed # 7877308 -- Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg. 1995 Mar;109(3):473-83; discussion 483-5.

1994 -- Pubmed # 8187005 -- Clamon G, Herndon J, Eaton W, Rosenman J, Maurer LH, Cooper MR, Green MR. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. Cancer Invest. 1994;12(3):273-82.

1994 -- Pubmed # 8055445 -- Deutsch M, Crawford J, Leopold K, Wolfe W, Foster W, Herndon J, Blackwell S, Yost R. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer. 1994 Aug 15;74(4):1243-52.

1994 -- Pubmed # 8052875 -- Green MR, Kosty MP, Muscato JJ, Graziano S, Dillman RO, Clamon GH, Herndon J 2nd. Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience. Semin Oncol. 1994 Jun;21(3 Suppl 6):60-5.

1994 -- Pubmed # 8201372 -- Kosty MP, Fleishman SB, Herndon JE 2nd, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1994 Jun;12(6):1113-20.

1994 -- Pubmed # 8118823 -- Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH. Alterations of the TP53 gene in human gliomas. Cancer Res. 1994 Mar 1;54(5):1324-30.

1994 -- Pubmed # 8083077 -- Seagren SL, Herndon JE, Baeker JR, Boles M, Chung C, Green MR. Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636. Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1085-8.

1994 -- Pubmed # 8021735 -- Vogelzang NJ, Weissman LB, Herndon JE 2nd, Antman KH, Cooper MR, Corson JM, Green MR. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol. 1994 Jul;12(7):1436-42.

1994 -- Pubmed # 8032544 -- Wheeler RH, Herndon JE, Clamon GH, Green MR. A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study. J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):212-6.

1993 -- Pubmed # 8336195 -- Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE 2nd, Aisner J, Ellison RR, Leone L. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993 Aug;11(8):1559-65.

1993 -- Pubmed # 8381188 -- Clamon G, Herndon J, Perry MC, Ozer H, Kreisman H, Maher T, Ellerton J, Green MR. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. J Natl Cancer Inst. 1993 Feb 17;85(4):316-20.

1993 -- Pubmed # 8389667 -- Graziano SL, Herndon JE 2nd, Richards F 2nd, DiFino S, Modeas C, Duggan DB, Green MR. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. Cancer. 1993 Jul 1;72(1):62-8.

1993 -- Pubmed # 8392285 -- Halperin EC, Gaspar L, Imperato J, Salter M, Herndon J 2nd, Dowling S. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. Am J Clin Oncol. 1993 Aug;16(4):277-83.

1993 -- Pubmed # 8229122 -- Kornblith AB, Hollis DR, Zuckerman E, Lyss AP, Canellos GP, Cooper MR, Herndon JE 2nd, Phillips CA, Abrams J, Aisner J. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol. 1993 Nov;11(11):2081-9.

1993 -- Pubmed # 8418246 -- Schold SC Jr, Herndon JE, Burger PC, Halperin EC, Vick NA, Cairncross JG, Macdonald DR, Dropcho EJ, Morawetz R, Bigner DD. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. J Clin Oncol. 1993 Jan;11(1):77-83.

1992 -- Pubmed # 1326224 -- Lyss AP, Perry MC, Goutsou M, Propert K, Herndon JE 2nd, Mason-Coughlin K, Green MR. Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B. Am J Clin Oncol. 1992 Oct;15(5):399-404.

1992 -- Pubmed # 1533174 -- Panella TJ, Smith DC, Schold SC, Rogers MP, Winer EP, Fine RL, Crawford J, Herndon JE 2nd, Trump DL. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res. 1992 May 1;52(9):2456-9.

1992 -- Pubmed # 1632416 -- Sketch MH Jr, Quigley PJ, Perez JA, Davidson CJ, Muhlestein JB, Herndon JE 2nd, Glower DD, Phillips HR, Califf RM, Stack RS. Angiographic follow-up after internal mammary artery graft angioplasty. Am J Cardiol. 1992 Aug 1;70(3):401-3.

1992 -- Pubmed # 1321893 -- Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Modeas C, Green MR. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol. 1992 Aug;10(8):1237-44.

1992 -- Pubmed # 1333267 -- Vokes EE, Lyss AP, Herndon JE 2nd, Cooper B, Perry MC, Vinciguerra V, Mason-Coughlin K, Green MR. Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. Ann Oncol. 1992 Nov;3(9):727-32.

1991 -- Pubmed # 1858036 -- Davidoff AM, Herndon JE 2nd, Glover NS, Kerns BJ, Pence JC, Iglehart JD, Marks JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery. 1991 Aug;110(2):259-64.

1991 -- Pubmed # 1660354 -- Doll D, Goutsou M, Graziano S, Ellerton J, Bitran J, Modeas C, Herndon J, Perry M, Green M. Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. Cancer Chemother Pharmacol. 1991;29(1):71-4.

1991 -- Pubmed # 1658684 -- Glantz MJ, Burger PC, Herndon JE 2nd, Friedman AH, Cairncross JG, Vick NA, Schold SC Jr. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology. 1991 Nov;41(11):1741-4.

1991 -- Pubmed # 1929205 -- Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC, Herndon JE 2nd, Meisler WJ, Schold SC Jr. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol. 1991 Apr;29(4):347-55.

1991 -- Pubmed # 1927964 -- Nelson CL, Herndon JE, Mark DB, Pryor DB, Califf RM, Hlatky MA. Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. Am J Cardiol. 1991 Oct 1;68(9):973-5.

1990 -- Herndon JE 2nd, Harrell FE Jr.  The restricted cubic spline hazard model.  Communications in Statistics:  Theory and Methods.  1990; 19(2): 639-63.

--